SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalImmunomedics (IMMU) - moderated


Previous 10 Next 10 
To: idahoranch1 who wrote (45916)4/26/2018 5:42:27 PM
From: erickerickson
9 Recommendations   of 58428
 
I think the other interesting thing about the short numbers is the increase lately. The month of March saw, what, a 2M+ increase in short positions? I find it unlikely that those are covered. Unlike quite a number of the number of short shares we've had for a long time, these are much more risky.

I agree with Mr. Ranch though: Unlike in the past, I don't think they're as much of a concern for a number of reasons:

1> there's a higher percentage of shares held by institutions which I think are less inclined to panic. Witness the drop in March, no real "run for the exits" reactions.

2> 50% swings are harder to "encourage" by shorting at this point. IMMU's corporate strength is vastly improved; inducing panic is harder. We're not in danger of getting "going concern" letters.

3> Unlike in the past, someone shorting IMMU has to be concerned about a perfect storm of good news.

Likely/expected:
> BLA submission
> ASCO presentation
> BLA approval

Possible
> BTD for UC
> BTD (or good news) for hormone receptor positive breast cancer (WOW!)
> Partnerships for other compounds
> news about 132 for other indications

All the while without any fear that we'd run out of money before year's end (pick your year in the past). Spending will (and already has) increased, but there's a lot of money in the bank.

Not to mention the quality of the new people on boarded recently. It's hard to imagine they're either desperate or being fooled by smoke and mirrors; I'm pretty confident theres some "there" there.

And I do have to say I still have whiplash from how expectations are changing. In the past, any quick jumps were untrustworthy; I kept wondering when the bad news would come along and depress the price again.

Now we get good news and, well, I rather expect more good news. At least that's the hope.

And anyone notice that when we get good news it's much more likely that the price increases? What's with that? More whiplash...

Erick

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: erickerickson who wrote (45917)4/26/2018 7:00:03 PM
From: duwhee
   of 58428
 
Good news was met with a wave of short selling and a drop in the share price because the smart money was on the ineptitude of the now defunct G dynasty.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: duwhee who wrote (45918)4/26/2018 9:06:01 PM
From: duwhee
   of 58428
 
I just wanted to use the word "defunct" in a sentence involving the G's.
My bucket list is shallow

Share RecommendKeepReplyMark as Last Read


From: KeeptheFaith4/26/2018 9:21:40 PM
2 Recommendations   of 58428
 
Are the next 6 weeks the most important in IMMU history?

With exception of the Gold/White slate voting, I believe the next 6 weeks contain the most important time in IMMU history. One could argue the PIII data on Epratuzumab for Lupus; but I feel that was like a blind squirrel up to bat against MLB pitching.

The next 6 weeks holds:
AA filing TNBC
ASCO presentation for wider range of breast cancer use
Possible updates on UC or other indications

And we have a MLB batter standing in the box ready to take a swing vs the previous unmentionables. A sharp single with AA would be nice but you never know when we may hit one over the fence (I prefer not focus on negative results).

-KTF

Share RecommendKeepReplyMark as Last Read


From: winners184/26/2018 10:24:13 PM
10 Recommendations   of 58428
 
start recruiting commercial team
immunomedics.com

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


To: winners18 who wrote (45921)4/27/2018 7:58:56 AM
From: sogwap1
2 Recommendations   of 58428
 
Exciting times !

Share RecommendKeepReplyMark as Last Read


To: winners18 who wrote (45921)4/27/2018 11:12:59 AM
From: Fitzhughlaw
9 Recommendations   of 58428
 
But wait - there's more! Posted today, and a position that would appear to be needed only if an entity had an approved drug (and is consonant with Pehl's remarks in the December of 2016 investor event when he mentioned the importance of reimbursement):

Senior Director Government Pricing and Market Access

Job Locations US-NJ-Morris Plains
Posted Date 4 hours ago(4/27/2018 7:07 AM)

Job ID 2018-1114 # of Openings 1 Category Marketing

Overview

We currently seek motivated professionals who share our passion for science and our dedication to improving the lives of cancer patients. The Sr. Director Government Pricing and Market Access, is a key leadership position within the Immunomedics commercial team. The position will report in to the Vice President Sales and Marketing. The responsibilities of this position are as follows:

Responsibilities

Responsible for overseeing the functions of government price calculation and reporting and commercial and government chargeback and rebate operations, including the people, process, policies, data and systems governing each of these functions. Provide leadership and serve as primary point of expertise in support of the build-out of Immunomedics’ government pricing, claims process, and chargebacks validation capabilities. Directly manage the outsourced services provider(s) that perform the below tasks:
  • All government pricing calculations (including, but not limited to the calculations and reporting of Best Price (BP), Average Manufacturer Price (AMP) (including both types of AMPs), Unit Rebate Amounts (URAs), Public Health Service price (340B/PHS), Average Sales Price (ASP), Non-Federal Average Manufacturer’s Price (Non FAMPs) (including wholesaler and non-wholesaler methods, Federal Ceiling Price (FCP), Federal Supply Schedule (FSS), and required state reporting for applicable products and submissions
  • FSS contract administration and management, including tracking customer monitoring, and IFF calculation and paymentMedicaid claims processing, including receipt, analysis, payment, and dispute resolutionAwarded State Supplementals programs claims processing, including receipt, analysis, payment, and dispute resolution
  • Tricare and Medicare Coverage Gap Discount Program claims processing and paymentCommercial managed care and Medicare Part D rebate claims processing and payment
  • Chargebacks validation in the form of COT assignment verification and contract eligibility management, including, but not limited to 340B/PHS and FSS contractsResponsible for tracking internally key information such as contract parameters and sharing the information with the outsourced service provider(s) so they are updated in a timely manner where it will not impact government price calculation development, chargeback and/or rebate processingManage and verify accuracy of all government price calculations, including submission of product, pricing, and other pertinent data (at a component level); working with the outsourced services provider(s) to ensure accuracy of the inputs and final price pointsManage and verify detailed data analysis of sales data, chargeback data, fee payment data, rebate data and other elements to ensure accuracy of the calculation and/explain variance differences

[Remainder of Description Omitted; source: immunomedics.com]

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Fitzhughlaw who wrote (45923)4/27/2018 11:40:17 AM
From: dorightbythem
1 Recommendation   of 58428
 
EU hires would be nice to see as well.

Share RecommendKeepReplyMark as Last Read


From: dorightbythem4/27/2018 11:43:28 AM
5 Recommendations   of 58428
 
Curious to know; Poll: How many here received an Email from the Company with regards to Oral Presentation of 132 at ASCO ? Please recommend if answer is Yes.

Another nice change.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: dorightbythem who wrote (45925)4/27/2018 12:15:43 PM
From: Fitzhughlaw
12 Recommendations   of 58428
 
I got a bootleg copy from another source. What intrigued me about the event is that in addition to Doctor Vahdat, who was one of the panelists at the December event after the SABCS, Dr. Tagawa will be participating, and he was previously featured in the January of 2017 release that updated SG as follows:

"In addition to TNBC, Immunomedics is making progress with IMMU-132 across the other three advanced indications. In patients with urothelial cancer, especially metastatic urinary bladder cancer, Dr. Scott T. Tagawa, Associate Professor of Medicine and Urology, Weill Cornell Medical College, and Attending Physician, New York-Presbyterian Hospital, New York, reported on 27 assessable patients from more than 40 patients enrolled. The objective response rate was 33%, including one complete and eight partial remissions. The duration of objective response was a median of 7.5 months, with one patient with a partial response approaching 17 months. The clinical benefit rate at six months or later was 59%, but 10 patients are still under therapy. Overall, 70% of the patients showed tumor shrinkage from baseline with IMMU-132 therapy. The median PFS and OS on an ITT basis were seven and almost 16 months, respectively. The safety profile was similar to the findings in patients with TNBC.

“These patients had a median of two prior therapies and had extensive metastatic disease. While patients with metastatic urothelial cancer respond well to initial therapy with a platinum-containing regimen, few options are available after they become refractive. The recent approval of an immune checkpoint inhibitor has been an important advance, but only a fraction of patients respond. In our trial, we had two such patients who were unresponsive to this therapy but showed tumor shrinkage with IMMU-132,” Dr. Tagawa said: “I am impressed with the results we have seen in this difficult-to-treat population and we continue to enroll these advanced patients in order to better position this new agent in the management of this disease, either as a second line therapy or perhaps someday in combination with chemotherapy or an immune checkpoint inhibitor.” Source: sec.gov

Also, another shareholder sent me this earlier today - Dr. Tagawa's remarks in February of 2017, and thus although dated and only about 90 seconds, is worth a look: https://www.youtube.com/watch?v=Jw72tz5tRek. Also, here's one from 2016, and it's interesting to see his initial thoughts on SG's potential: youtube.com

Thus, because of his presence at this impending event and ongoing involvement with SG in UTC, I'm inferring that the investor event won't be limited to breast cancers, but will include an update on urothelial.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)
Previous 10 Next 10